2006 survey
2013 survey
Patients treated for HCV infection
Patients NOT treated for HCV infection
Total (%)
Patients treated for HCV infection
Patients NOT treated for HCV infection
Total (%)
P
*
Number
%
Number
%
Number
%
Number
%
HCV RNA copies/ml
Positive
141
-
102
-
243
94
-
71
-
165
0.84
<800,000
64
-
53
-
117
37
-
30
-
67
1
>800,000
77
-
49
-
126
55
-
37
-
92
0.89
Negative
64
-
26
-
90
104
-
48
-
152
0.77
Not done/missing
17
-
33
-
40
12
-
11
-
23
0.2
HCV genotype
Genotype 1
105
49
66
50
171 (50)
116
60
44
56
160 (59)
0.036
Genotype 2
22
10
7
5
29 (8)
6
3
1
1
7 (3)
1
Genotype 3
61
29
32
24
93 (27)
35
18
19
24
54 (20)
1
Genotype 4
25
12
27
20
52 (15)
34
18
15
19
49 (17)
0.043
Genotype 5
0
0
0
0
0 (0)
1
1
0
0
1 (1)
.
Genotype 6
0
0
0
0
0 (0)
0
0
0
0
0
.
Liver damage assessment
Liver biopsy and/or non invasive markers
213
100
112
100
325 (78)
175
100
78
100
253 (74)
0.37
Liver biopsy only
106
47
41
25
147 (35)
14
8
4
5
18 (5)
0.78
Non invasive markers only
40
18
53
32
93 (22)
87
50
57
73
144 (42)
0.011
Both
67
30
18
11
85 (20)
73
42
16
21
89 (26)
0.7
None
14
6
52
32
66 (16)
21
12
30
38
51 (15)
0.025
Table 2:
Main characteristics of HCV infection in HIV-HCV co-infected patients, in those who had received HCV treatment and those who had never been treated in the 2006 and 2013 surveys.*P corresponds to the comparison between 2006 and 2013 surveys.
Goto home»
